

Fragile sites are preferential targets for integrations of MLV vectors in gene therapy

AC Bester, M Schwartz, M Schmidt, A Garrigue, S Hacein-Bey-Abina, M Cavazzana-Calvo, N Ben-Porat, C Von Kalle, A Fischer and B Kerem

Gene Therapy (2007) **14**, 282. doi:10.1038/sj.gt.3302904

Correction to: *Gene Therapy* (2006) **13**, 1057–1059. doi:10.1038/sj.gt.3302752

Since the above publication the authors have noticed an error in the first DNA marker of FRA11E in Supplementary Table 1S. The correct table is shown below:

Table 1S Analyzed sequences from common fragile site regions and number of MLV integrations in each fragile region

	Chromosomal position ^a	First DNA marker ^b	Last DNA marker ^b	Reference ^e	CD3+ ^c	HeLa ^d
FRA2G	chr2: 169,452,095- 170,292,618	RH91148	RH1293	5	1	1
FRA3B	chr3: 59,594,241- 64,182,258	D3S3577	D3S1287	6		1
FRA4F	chr4: 89,694,006- 97,605,145	RH94252	D4S2407	7	1	3
FRA6E	chr6: 160,551,547- 163,760,142	RH92608	RH63999	8	2	
FRA6F	Chr6: 106,922,988-112,526,158	SHGC-140029	D6S1259	9,10	1	1
FRA7E	chr7: 79,882,815-84,580,600	swss4015	SHGC-104456	11		6
FRA7G	chr7: 109,809,464- 116,030,383	RH122988	D7S2863	12,13		2
FRA7H	chr7: 129,368,585-130,393,035	A006N09	D7S2531	2	2	1
FRA7I	chr7: 144,322,489-145,530,291	D7S1477	D7S739	14		
FRA8C	chr8: 124,267,550-128,310,523	D8S1160	SHGC-130454	13		2
FRA9E	chr9: 106,403,642-116,118,637	SHGC-106699	RH62868	15	3	2
FRA11E	chr11: 31,953,729 -33,948,551	D11S1964	D11S4965	This study	5	2
FRA16D	chr16: 76,161,223-77,681,818	D16S3138	D16S516	16,17		
FRAXB	chrX: 6,827,880- 7,285,010	DXS1130	DXS1133	18		
					15	21

^aPositions are denoted according to the 2004 freeze of the UCSC human sequence assembly.

^bDNA markers mapped to the ends of the analyzed sequence.

^cMLV integrations in CD3+ cells of nine treated SCID-X1 patients.

^dMLV integrations in HeLa cells, from Wu et al.19

^eSupplementary reference list.

The authors would like to apologise for this error.